Targeted contrast agents for MRI of amyloid deposition
US11116854B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2021 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Jan 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K49/108
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.